Price | 1W % | 1M % | 3M % | 6M % | 1Y % | YTD % |
|---|---|---|---|---|---|---|
-- | -- | -- | -- | -- | -- | -- |
AI Generated Qualitative Analysis
Your time is precious, so save it. Use AI to get the most important information from the business.
Learn about Renalytix Plc
Renalytix Plc News
Renalytix Plc Quantitative Score
About Renalytix Plc
Renalytix Plc develops artificial intelligence-enabled in vitro diagnostic solutions for kidney diseases. The company offers KidneyIntelX, a diagnostic platform that employs an artificial intelligence-enabled algorithm that combines various data inputs, including validated blood-based biomarkers, inherited genetics and personalized patient data from electronic health record systems to generate a unique patient risk score. Its products are used in kidney disease diagnosis and prognosis, clinical care, patient stratification for drug clinical trials, and drug target discovery. Renalytix AI plc has a license agreement with Mount Sinai Health System to develop and commercialize licensed products in connection with the application of artificial intelligence for the diagnosis of kidney disease; Joslin Diabetes Center, Inc. for developing and commercializing products for diagnosing and predicting kidney disease using biomarkers; and Kantaro Biosciences LLC for developing and commercializing laboratory tests for the detection of antibodies against SARS-CoV-2. The company also has a partnership agreement with Atrium Health, Wake Forest Baptist Health, and Wake Forest School of Medicine to implement an advanced clinical care model designed to improve kidney health and reduce kidney disease progression and kidney failure in high-risk populations. The company was formerly known as Renalytix AI plc and changed its name to Renalytix Plc in June 2021. Renalytix Plc was incorporated in 2018 and is headquartered in New York, New York.
Renalytix Plc Earnings & Revenue
What’s This Company Really Worth? Find Out Instantly.
Warren Buffett’s go-to valuation method is Discounted Cash Flow (DCF). Our tool makes it effortless — no spreadsheets, just answers in a few clicks.
Renalytix Plc Financials
Table Compare
Compare RNLX metrics with: | |||
|---|---|---|---|
Earnings & Growth | RNLX | None | |
EPS (TTM) YoY Growth | -- | -- | |
Revenue (TTM) YoY Growth | -- | -- | |
Valuation (TTM) | RNLX | None | |
Price/Earnings Ratio | -- | -- | |
Price/Sales Ratio | -- | -- | |
Profitability & Efficiency (TTM) | RNLX | None | |
Net Profit Margin | -- | -- | |
Return on Equity | -- | -- | |
Financial Health (TTM) | RNLX | None | |
Debt/Assets Ratio | -- | -- | |
Assets/Liabilities Ratio | -- | -- | |
Renalytix Plc Income
Renalytix Plc Balance Sheet
Renalytix Plc Cash Flow
Renalytix Plc Financials Over Time
Analysts Rating
Strong Buy
Buy
Hold
Sell
Strong Sell
Metrics Scores
| Metrics | Score |
|---|---|
| Discounted Cash Flows | Strong Sell |
| Return on Equity | Strong Buy |
| Return on Assets | Strong Sell |
| Debt/Equity Ratio | Strong Sell |
| Price/Earnings Ratio | Strong Sell |
| Price/Book Ratio | Strong Sell |
Price Targets
Disclaimer: This 3rd party analysis information is for reference only and does not constitute investment advice.
Historical Market Cap
Shares Outstanding
Renalytix Plc Executives
| Name | Role |
|---|---|
| Mr. James R. McCullough M.B.A. | Chief Executive Officer & Chairman |
| Mr. Salim Gulamabbas Hamir F.C.A. | Company Secretary |
| Mr. Joel R. Jung MBA | Interim Chief Financial Officer & Principal Accounting Officer |
| Mr. Howard B. Doran Jr. | President |
| Dr. Michael J. Donovan M.D., Ph.D. | Chief Medical Officer |
| Name | Role | Gender | Date of Birth | Pay |
|---|---|---|---|---|
| Mr. James R. McCullough M.B.A. | Chief Executive Officer & Chairman | Male | 1968 | 1.04M |
| Mr. Salim Gulamabbas Hamir F.C.A. | Company Secretary | Male | -- | |
| Mr. Joel R. Jung MBA | Interim Chief Financial Officer & Principal Accounting Officer | Male | 1958 | -- |
| Mr. Howard B. Doran Jr. | President | Male | 1961 | -- |
| Dr. Michael J. Donovan M.D., Ph.D. | Chief Medical Officer | 1954 | -- |
Renalytix Plc Insider Trades
| Date | 1 Nov |
| Name | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI |
| Role | 10 percent owner |
| Transaction | Acquired |
| Type | J-Other |
| Shares | 13366750 |
| Date | 11 Jun |
| Name | Jung Joel R |
| Role | Interim Chief Financial Office |
| Transaction | Acquired |
| Type | A-Award |
| Shares | 60000 |
| Date | 27 May |
| Name | Jung Joel R |
| Role | |
| Transaction | Disposed |
| Type | |
| Shares | 0 |
| Date | 24 Apr |
| Name | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI |
| Role | 10 percent owner |
| Transaction | Acquired |
| Type | J-Other |
| Shares | 9360374 |
| Date | 20 Nov |
| Name | Coste Catherine |
| Role | Director |
| Transaction | Acquired |
| Type | A-Award |
| Shares | 95000 |
| Date | Name | Role | Transaction | Type | Shares |
|---|---|---|---|---|---|
| 1 Nov | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI | 10 percent owner | Acquired | J-Other | 13366750 |
| 11 Jun | Jung Joel R | Interim Chief Financial Office | Acquired | A-Award | 60000 |
| 27 May | Jung Joel R | Disposed | 0 | ||
| 24 Apr | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI | 10 percent owner | Acquired | J-Other | 9360374 |
| 20 Nov | Coste Catherine | Director | Acquired | A-Award | 95000 |